Dr. Joel Dudley is associate professor of genetics and genomic sciences and director of biomedical informatics at Mount Sinai School of Medicine, New York (NY, USA).Dr. Laura Berliocchi is associate professor of pharmacology at the Department of Health Sciences, Magna Graecia University (Catanzaro, Italy).

This excellent book is a must read for those interested in drug-repositioning and those involved in the hunt for new effective neurotherapeutics. The introductory sections of the book provide not only a clear explanation of the merits of repositioning but also an honest consideration of the difficulties of the approach. This is well illustrated by examples from the fields of Alzheimer’s and Parkinson’s describing successes and failures. Also introduced is the value of drug-repositioning to not-for profit organisations. Which adds to those who are involved in medical charity research to list of those who should read this publication. For the reader whose interest is piqued by the possibilities of drug repositioning and want to know more of the mechanics following chapters explore a variety of techniques that can be adopted for the identification of candidate repositioned therapies. Again, these an honest consideration with both pro and cons described. This makes the publication useful reading for any interested in repositioning irrespective of their field of interest. The latter sections focus on repositioning for a very diverse range of CNS conditions. These include Parkinson’s, Alzheimer’s, Huntingdon’s, ALS, Spinal muscular atrophy and Ischaemic injury. For those with specific interests in any of the above this is a useful work. But in addition, I would recommend to those with a specific CNS disease interest reading the other chapters as they provide a potentially useful insight into methods and approaches than could be adopted within a specific interest.Taken together this is valuable read and reference work for a diverse readership.- Dr Alan Rothaul, Re-PharmDrug repositioning, also known as repurposing, seems an easy and straight forward route for the successful development of drugs. However, aspects of value creation and sound business cases are still essential, even if a drug has been fully or partly developed before.Complexity is added to this situation by applying repurposing to the area of neurodegenerative diseases: pathogenesis of Parkinson’s, Alzheimer’s and other neurologic diseases of the higher ages are still poorly understood. Nevertheless, there is hope in repurposing even for this very difficult indication area, increasingly neglected by pharma companies due to extremely high development costs and numerous failures to successfully develop drugs. Joel Dudley and Laura Berliocchi's book is disentangling the complexity and shows with many positive examples, that repurposing is possible, needs courage and attention to detail and sometimes also happens just by serendipity. Systematic approaches to drug repositioning, as well as funding mechanisms for repurposing projects and options to gain IP protection for existing drugs are comprehensively explained. Reading is highly recommended to newcomers in the field of therapy development for neurodegenerative indications as well as established scientists and medical doctors wishing to gain broad insight into the drug repositioning topic illustrated with plenty of case studies.- Dr Bernadett Simon, PhD, RTTP, Head of Technology Transfer at DZNE, Bonn, Germany

• Section I The Rationale and Economicsof Drug RepositioningChapter 1 Scientific and Commercial Value of Drug RepurposingDavid CavallaChapter 2 Repurposing for Alzheimer’s and Parkinson’s Diseases: TheIdeas, the Pipeline, the Successes, and the DisappointmentsHermann MuckeChapter 3 Contribution of Not-for-Profit Organizations to Drug RepurposingBruce BloomSection II Repositioning Approaches andTechnologies: From Serendipity toSystematic and Rational StrategiesChapter 4 Systematic Drug RepositioningSpyros N. Deftereos, Aris Persidis, Andreas Persidis,Eftychia Lekka, Christos Andronis, and Vassilis VirvillisChapter 5 Technical Tools for Computational Drug RepositioningFrancesco NapolitanoChapter 6 RNAi Screening toward Therapeutic Drug RepurposingNichole Orr-Burks, Byoung-Shik Shim, Olivia Perwitasari,and Ralph A. TrippChapter 7 Phenotypic ScreeningChristine M. Macolino-Kane, John R. Ciallella,Christopher A. Lipinski, and Andrew G. ReaumeSection III Drug Repositioning forNervous System DiseasesChapter 8 A Case Study: ChlorpromazineFrancisco López-Munoz, Cecilio Álamo,and Silvia E. García-RamosChapter 9 Drug Repurposing for Central Nervous System Disorders: APillar of New Drug DiscoveryMondher Toumi, Aleksandra Caban, Anna Kapuśniak,Szymon Jarosławski, and Cecile RémuzatChapter 10 Repurposing Opportunities for Parkinson’s Disease TherapiesGiulia Ambrosi, Silvia Cerri, and Fabio BlandiniChapter 11 Drug Candidates for Repositioning in Alzheimer’s DiseaseMaria P. del Castillo-Frias and Andrew J. Doig

Dr. Joel Dudley is associate professor of genetics and genomic sciences and director of biomedical informatics at Mount Sinai School of Medicine, New York (NY, USA).Dr. Laura Berliocchi is associate professor of pharmacology at the Department of Health Sciences, Magna Graecia University (Catanzaro, Italy).

This excellent book is a must read for those interested in drug-repositioning and those involved in the hunt for new effective neurotherapeutics. The introductory sections of the book provide not only a clear explanation of the merits of repositioning but also an honest consideration of the difficulties of the approach. This is well illustrated by examples from the fields of Alzheimer’s and Parkinson’s describing successes and failures. Also introduced is the value of drug-repositioning to not-for profit organisations. Which adds to those who are involved in medical charity research to list of those who should read this publication. For the reader whose interest is piqued by the possibilities of drug repositioning and want to know more of the mechanics following chapters explore a variety of techniques that can be adopted for the identification of candidate repositioned therapies. Again, these an honest consideration with both pro and cons described. This makes the publication useful reading for any interested in repositioning irrespective of their field of interest. The latter sections focus on repositioning for a very diverse range of CNS conditions. These include Parkinson’s, Alzheimer’s, Huntingdon’s, ALS, Spinal muscular atrophy and Ischaemic injury. For those with specific interests in any of the above this is a useful work. But in addition, I would recommend to those with a specific CNS disease interest reading the other chapters as they provide a potentially useful insight into methods and approaches than could be adopted within a specific interest.Taken together this is valuable read and reference work for a diverse readership.- Dr Alan Rothaul, Re-PharmDrug repositioning, also known as repurposing, seems an easy and straight forward route for the successful development of drugs. However, aspects of value creation and sound business cases are still essential, even if a drug has been fully or partly developed before.Complexity is added to this situation by applying repurposing to the area of neurodegenerative diseases: pathogenesis of Parkinson’s, Alzheimer’s and other neurologic diseases of the higher ages are still poorly understood. Nevertheless, there is hope in repurposing even for this very difficult indication area, increasingly neglected by pharma companies due to extremely high development costs and numerous failures to successfully develop drugs. Joel Dudley and Laura Berliocchi's book is disentangling the complexity and shows with many positive examples, that repurposing is possible, needs courage and attention to detail and sometimes also happens just by serendipity. Systematic approaches to drug repositioning, as well as funding mechanisms for repurposing projects and options to gain IP protection for existing drugs are comprehensively explained. Reading is highly recommended to newcomers in the field of therapy development for neurodegenerative indications as well as established scientists and medical doctors wishing to gain broad insight into the drug repositioning topic illustrated with plenty of case studies.- Dr Bernadett Simon, PhD, RTTP, Head of Technology Transfer at DZNE, Bonn, Germany

• Section I The Rationale and Economicsof Drug RepositioningChapter 1 Scientific and Commercial Value of Drug RepurposingDavid CavallaChapter 2 Repurposing for Alzheimer’s and Parkinson’s Diseases: TheIdeas, the Pipeline, the Successes, and the DisappointmentsHermann MuckeChapter 3 Contribution of Not-for-Profit Organizations to Drug RepurposingBruce BloomSection II Repositioning Approaches andTechnologies: From Serendipity toSystematic and Rational StrategiesChapter 4 Systematic Drug RepositioningSpyros N. Deftereos, Aris Persidis, Andreas Persidis,Eftychia Lekka, Christos Andronis, and Vassilis VirvillisChapter 5 Technical Tools for Computational Drug RepositioningFrancesco NapolitanoChapter 6 RNAi Screening toward Therapeutic Drug RepurposingNichole Orr-Burks, Byoung-Shik Shim, Olivia Perwitasari,and Ralph A. TrippChapter 7 Phenotypic ScreeningChristine M. Macolino-Kane, John R. Ciallella,Christopher A. Lipinski, and Andrew G. ReaumeSection III Drug Repositioning forNervous System DiseasesChapter 8 A Case Study: ChlorpromazineFrancisco López-Munoz, Cecilio Álamo,and Silvia E. García-RamosChapter 9 Drug Repurposing for Central Nervous System Disorders: APillar of New Drug DiscoveryMondher Toumi, Aleksandra Caban, Anna Kapuśniak,Szymon Jarosławski, and Cecile RémuzatChapter 10 Repurposing Opportunities for Parkinson’s Disease TherapiesGiulia Ambrosi, Silvia Cerri, and Fabio BlandiniChapter 11 Drug Candidates for Repositioning in Alzheimer’s DiseaseMaria P. del Castillo-Frias and Andrew J. Doig